Hematologic Malignancy
Plasma Cell Neoplasm
CI-CAN-00006438Explore in graph →
HematologicNon-malignant831 active trials25 approved drugs26 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006438Explore in graph →
Clinical trials
3,420 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00135187 | Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma | completed | N/A | 30 | University of Michigan Rogel Cancer CenterOTHER | 1 | Feb 7, 2012 | clinicaltrials |
| NCT00029224 | Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions | completed | Phase 4 | 500 | NovartisINDUSTRY | 1 | Feb 1, 2012 | clinicaltrials |
| NCT00608907 | An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib) | completed | Phase 1 | 61 | Millennium Pharmaceuticals, Inc.INDUSTRY | 5 | Jan 30, 2012 | clinicaltrials |
| NCT00531453 | A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) in Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 98 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 26, 2012 | clinicaltrials |
| NCT00427765 | Busulfan Plus Melphalan Conditioning Regimen for Lymphoid Malignancies or Multiple Myeloma | completed | Phase 2 | 168 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 19, 2012 | clinicaltrials |
| NCT00048230 | PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 3 | 620 | Millennium Pharmaceuticals, Inc.INDUSTRY | 13 | Jan 13, 2012 | clinicaltrials |
| NCT00063726 | A Study of PS-341 Given to Patients With Multiple Myeloma Who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039 | completed | Phase 3 | 600 | Millennium Pharmaceuticals, Inc.INDUSTRY | 13 | Jan 13, 2012 | clinicaltrials |
| NCT01175278 | Vertebral Augmentation With Kyphoplasty vs Nonsurgical Mgmt for Vertebral Body Compression Fractures | withdrawn | N/A | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 0 | Jan 12, 2012 | clinicaltrials |
| NCT00473551 | Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies | terminated | Phase 1 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 19, 2011 | clinicaltrials |
| NCT00760370 | Comparison of Zometa Retention and Effect in Multiple Myeloma and Breast Cancer | completed | Phase 2 | 60 | Vejle HospitalOTHER | 1 | Dec 7, 2011 | clinicaltrials |
| NCT00388999 | Intravenous rhMBL in Patients With Multiple Myeloma Receiving Chemotherapy Followed by Stem Cell Transplant | completed | Phase 1 | 46 | Enzon Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 5, 2011 | clinicaltrials |
| NCT00113841 | Curcumin (Diferuloylmethane Derivative) With or Without Bioperine in Patients With Multiple Myeloma | completed | N/A | 42 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 23, 2011 | clinicaltrials |
| NCT00478777 | A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma | completed | Phase 3 | 150 | Celgene CorporationINDUSTRY | 1 | Nov 3, 2011 | clinicaltrials |
| NCT00281476 | The Effect of High Dose Simvastatine on Multiple Myeloma | completed | Phase 1 / Phase 2 | 10 | Vejle HospitalOTHER | 0 | Nov 1, 2011 | clinicaltrials |
| NCT00722566 | A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Treated Multiple Myeloma | completed | Phase 3 | 222 | Millennium Pharmaceuticals, Inc.INDUSTRY | 3 | Oct 10, 2011 | clinicaltrials |
| NCT00562224 | Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients | completed | Phase 1 | 36 | Pharmacyclics LLC.INDUSTRY | 1 | Sep 28, 2011 | clinicaltrials |
| NCT01042717 | Study of the Best Timing for Plerixafor in Autologous Hematopoietic Stem Cell Collection | unknown | N/A | 10 | Shi, Patricia, M.D.INDIV | 1 | Sep 27, 2011 | clinicaltrials |
| NCT01114048 | Early Response-adapted Intensification of Induction Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (MM)(KMM-97) | unknown | Phase 2 | 78 | Chonnam National University HospitalOTHER | 1 | Sep 22, 2011 | clinicaltrials |
| NCT01328236 | Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia(Bortezomib) | unknown | Phase 2 | 20 | Clinical Service, ChinaINDUSTRY | 1 | Sep 22, 2011 | clinicaltrials |
| NCT00443235 | GEM05 for Patients With Multiple Myeloma More Than 65 Years Old | completed | Phase 3 | 260 | PETHEMA FoundationOTHER | 1 | Sep 19, 2011 | clinicaltrials |
| NCT00652041 | Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma(TaCyDexVMP7) | completed | Phase 4 | 40 | PETHEMA FoundationOTHER | 1 | Sep 19, 2011 | clinicaltrials |
| NCT00504634 | Bortezomib (Velcade) Post Allogenic Peripheral Blood Stem Cell Transplantation for Myeloma | completed | Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 15, 2011 | clinicaltrials |
| NCT00113932 | UARK 2003-41: A Study of High-Dose Density Therapy in Patients With Multiple Myeloma | completed | Phase 2 | 140 | University of ArkansasOTHER | 1 | Sep 2, 2011 | clinicaltrials |
| NCT00118339 | Ice Chips or Saline Mouth Rinse in Reducing or Preventing Mucositis in Patients Receiving Melphalan and Autologous Stem Cell Transplant for Multiple Myeloma | completed | N/A | 41 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 1, 2011 | clinicaltrials |
| NCT01423344 | Clinical Evaluation of the Serum Free Light Chain Analysis | unknown | — | 30 | Charlotte Toftmann HansenOTHER | 1 | Aug 25, 2011 | clinicaltrials |
| NCT00431990 | A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma | unknown | Phase 1 / Phase 2 | 40 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Aug 12, 2011 | clinicaltrials |
| NCT00569868 | UARK 2005-05, Coagulation-Related Effects of Velcade Treatment in Patients With Relapsed or Refractory Multiple Myeloma | completed | N/A | 11 | University of ArkansasOTHER | 1 | Aug 12, 2011 | clinicaltrials |
| NCT00573391 | Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2 | terminated | Phase 3 | 5 | University of ArkansasOTHER | 1 | Aug 12, 2011 | clinicaltrials |
| NCT01002703 | Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 50 | University of LeipzigOTHER | 1 | Aug 12, 2011 | clinicaltrials |
| NCT00273936 | Trial of AVN-944 in Patients With Advanced Hematologic Malignancies | completed | Phase 1 | 72 | Vertex Pharmaceuticals IncorporatedINDUSTRY | 1 | Aug 4, 2011 | clinicaltrials |
| NCT00263484 | Higher Frequency Zoledronic Acid in the Treatment of Multiple Myeloma(dtZ) | completed | Phase 2 | 56 | Gleneagles HospitalOTHER | 3 | Jul 21, 2011 | clinicaltrials |
| NCT00104104 | A Multiple Myeloma Trial in Patients With Bone Metastases | completed | Phase 4 | 179 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 29, 2011 | clinicaltrials |
| NCT00546780 | A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse(BMS TIME-1) | completed | Phase 3 | 31 | Bristol-Myers SquibbINDUSTRY | 2 | Jun 28, 2011 | clinicaltrials |
| NCT00561743 | A Study Assessing Safety and Effectiveness of BORTEZOMIB Combination Therapy (Bortezomib + Doxorubicin Hydrochloride + Dexamethasone) in Previously Untreated Multiple Myeloma Patients | completed | Phase 2 | 50 | Janssen-Ortho Inc., CanadaINDUSTRY | 0 | Jun 21, 2011 | clinicaltrials |
| NCT00891280 | Dose-escalation Study of Oral CX-4945 | unknown | Phase 1 | 55 | Cylene PharmaceuticalsINDUSTRY | 1 | Jun 15, 2011 | clinicaltrials |
| NCT01199718 | Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 | 22 | Cylene PharmaceuticalsINDUSTRY | 1 | Jun 15, 2011 | clinicaltrials |
| NCT01116128 | Dasatinib in Combination With Melphalan and Prednisone to Treat Relapsed and Refractory Multiple Myeloma Patients(D-MP) | terminated | Phase 2 | 8 | Fondazione EMN Italy OnlusOTHER | 1 | Jun 14, 2011 | clinicaltrials |
| NCT00344422 | Vincristine, DOXIL (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 3 | 198 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 0 | Jun 10, 2011 | clinicaltrials |
| NCT01010880 | Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma Patients | completed | Phase 1 / Phase 2 | 16 | Biokine Therapeutics LtdINDUSTRY | 1 | Jun 10, 2011 | clinicaltrials |
| NCT01370434 | Two Cycles of PAD Combination by AHCT in MM(PADinMM) | completed | Phase 2 | 43 | Cooperative Study Group A for HematologyNETWORK | 1 | Jun 10, 2011 | clinicaltrials |
| NCT00270101 | The Effect of Epoetin Alfa on the Anemia of Patients With Multiple Myeloma | completed | Phase 3 | 156 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 0 | May 18, 2011 | clinicaltrials |
| NCT00270166 | The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy | completed | Phase 3 | 201 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 0 | May 18, 2011 | clinicaltrials |
| NCT00216697 | An Extension Study to Provide Bortezomib to Patients With Relapsed or Refractory Multiple Myeloma Who Previously Participated in a Bortezomib Phase I/II Study and Who May Benefit From Re-Treatment With or Continuation of Bortezomib Therapy | completed | Phase 2 | 13 | Janssen Pharmaceutical K.K.INDUSTRY | 0 | May 17, 2011 | clinicaltrials |
| NCT00752518 | A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients | completed | Phase 1 / Phase 2 | 35 | Janssen Pharmaceutical K.K.INDUSTRY | 0 | May 17, 2011 | clinicaltrials |
| NCT00577668 | A Pilot Study of the Combination of Melphalan, Bortezomib, Thalidomide and Dexamethasone (MEL-VTD) | withdrawn | Phase 2 | 0 | University of ArkansasOTHER | 1 | May 3, 2011 | clinicaltrials |
| NCT00216151 | Zoledronic Acid in the Management of Patients With Asymptomatic/Early Stage Multiple Myeloma | terminated | Phase 2 | 3 | Hoosier Cancer Research NetworkOTHER | 1 | May 2, 2011 | clinicaltrials |
| NCT01341262 | THAL-DEX Incorporated Into Double PBSC Autotransplantation for Untreated Multiple Myeloma (MM) | completed | Phase 2 | 378 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 0 | Apr 25, 2011 | clinicaltrials |
| NCT01296204 | Radioimmunotherapy (RIT) in MULTIPLE MYELOMA Using the Antibody B-B4 Radiolabelled With IODE 131(BB4) | completed | Phase 1 | 33 | Centre René GauducheauOTHER | 1 | Mar 22, 2011 | clinicaltrials |
| NCT00290095 | Quality of Life in Patients With Multiple Myeloma | completed | — | 260 | Ullevaal University HospitalOTHER | 1 | Mar 8, 2011 | clinicaltrials |
| NCT00772811 | Using Fludarabine and Melphalan Conditioning Regimen for CLL,Lymphoma,Multiple Myeloma(Flu-Mel) | completed | Phase 2 | 38 | Cooperative Study Group A for HematologyNETWORK | 1 | Feb 17, 2011 | clinicaltrials |
Data updated 22 days agoSource updated Feb 7, 2012source: clinicaltrials